Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State-Reference-Cited by-同舟云学术

Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State

Published:2021-06-24 Issue: Volume: Page:
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

McEwen Abbye E¹,Cohen Seth²,Bryson-Cahn Chloe²,Liu Catherine³,Pergam Steven A³,Lynch John²,Schippers Adrienne⁴,Strand Kathy⁴,Whimbey Estella²,Mani Nandita S²,Zelikoff Allison J⁵,Makarewicz Vanessa A⁵,Brown Elizabeth R³,Bakhash Shah A Mohamed¹,Baker Noah R¹,Castor Jared¹,Livingston Robert J¹,Huang Meei-Li¹,Jerome Keith R¹³,Greninger Alexander L¹³,Roychoudhury Pavitra¹³^ORCID

Affiliation:

1. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA

2. Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA

3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

4. Department of Infection Prevention and Employee Health, University of Washington Medical Center, Seattle, Washington, USA

5. Harborview Medical Center, University of Washington, Seattle, Washington, USA

Abstract

Abstract Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were due to variants of concern (VOCs) and had a median Ct of 20.2 (IQR, 17.1–23.3). When compared with 5174 contemporaneous samples sequenced in our laboratory, VOCs were significantly enriched among breakthrough infections (P < .05).

Funder

National Institutes of Health

UW-Fred Hutch CFAR New Investigator

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciab581/39513245/ciab581.pdf

Reference17 articles.

1. Target product profile analysis of COVID-19 vaccines in phase III clinical trials and beyond: an early 2021 perspective;Funk;Viruses,2021

2. Vaccine breakthrough infections with SARS-CoV-2 variants;Hacisuleyman,2021